Clinical Trial Detail

NCT ID NCT02596035
Title A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374)
Recruitment Active, not recruiting
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

renal cell carcinoma

Therapies

Nivolumab

Age Groups: adult

No variant requirements are available.